针对癌症免疫治疗的 TNFR2：最新进展和未来方向。
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.
发表日期：2024 Sep 02
作者：
Linxue Li, Ruiwei Ye, Yingying Li, Hanyu Pan, Sheng Han, Yiming Lu
来源：
Cellular & Molecular Immunology
摘要：
癌症是全球头号死亡原因，每年导致近 1000 万人死亡。免疫检查点阻断方法改变了许多肿瘤类型的治疗前景。然而，目前的免疫检查点抑制剂PD-1或CTLA-4还远远不能令人满意，因为免疫相关不良事件发生率较高（高达60%），而且在“冷”肿瘤微环境下效率低下。 TNFR2是一种新的有希望的肿瘤免疫靶点，最初于2017年被提出。它不仅促进肿瘤细胞增殖，还与Treg细胞的抑制功能相关，参与免疫抑制肿瘤微环境的发展。在临床前研究中，TNFR2 抗体疗法已证明单独有效或与经典 PD-1/CTLA-4 抗体联合使用时具有潜在的协同效应。本综述的重点是TNFR2疗法的特点、功能和最新进展，为下一代抗肿瘤替代疗法提供新方向。© 2024。作者。
Cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths every year. Immune checkpoint blockade approaches have changed the therapeutic landscape for many tumor types. However, current immune checkpoint inhibitors PD-1 or CTLA-4 are far from satisfactory, due to high immune-related adverse event incident (up to 60%) and the inefficiency in cases of "cold" tumor microenvironment. TNFR2, a novel hopeful tumor immune target, was initially proposed in 2017. It not only promotes tumor cell proliferation, but also correlates with the suppressive function of Treg cells, implicating in the development of an immunosuppressive tumor microenvironment. In preclinical studies, TNFR2 antibody therapy has demonstrated efficacy alone or a potential synergistic effect when combined with classical PD-1/ CTLA-4 antibodies. The focus of this review is on the characteristics, functions, and recent advancements in TNFR2 therapy, providing a new direction for the next generation of anti-tumor alternative therapy.© 2024. The Author(s).